Alternative dosing of dual PI3K and MEK inhibition in cancer therapy

BACKGROUND: PI3K/AKT/mTOR and RAS/RAF/MEK/ERK pathways are thought to be the central transducers of oncogenic signals in solid malignancies, and there has been a lot of enthusiasm for developing inhibitors of these pathways for cancer therapy. Some preclinical models have suggested that combining in...

Descripción completa

Detalles Bibliográficos
Autores principales: Jokinen, Elina, Laurila, Niina, Koivunen, Jussi P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3563486/
https://www.ncbi.nlm.nih.gov/pubmed/23259591
http://dx.doi.org/10.1186/1471-2407-12-612

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3563486/
https://www.ncbi.nlm.nih.gov/pubmed/23259591
http://dx.doi.org/10.1186/1471-2407-12-612

Ejemplares similares